Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?

Front Immunol · 2026 · PMC13176235 · PMID 42148079

Europe PMC DOI

hedged sentences

0.2820

closest p · 5.6× alpha

0.2820

boldest claim

The sentences

did not reach statistical significanceP= 0.282not close (p > 0.1)

16.7 months), though the difference did not reach statistical significance (P= 0.282, Figure 2B ).

also in 111,027 other papers

showed a trendP= 0.282not close (p > 0.1)

However, the combination group showed a trend toward improved OS (24.8 vs. 16.7 months, P= 0.282), with a significant benefit in BCLC-C patients (17.9 vs. 11.0 months, P= 0.048).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.